story of the week
Patient-Reported Outcomes and Hospitalization Data in Patients With HER2-Positive MBC Receiving Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study
Ann. Oncol 2023 May 11;[EPub Ahead of Print], G Curigliano, K Dunton, M Rosenlund, M Janek, J Cathcart, Y Liu, PA Fasching, H IwataFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.